Notification
No new Notification messages
Garuda Construction And Engineering IPO is Open!
Apply for the Garuda Construction And Engineering IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
Trade Now, Pay Later with up to 4x Leverage
Never miss a good trading opportunity due to low funds with our MTF feature.

Dr. Reddy’s Unit Shows Promising Trial Results For Blood Cancer Treatment

Listen to our Podcast: Grow your wealth and keep it secure.

0:00 / 0:00

Synopsis:

Dr. Reddy's subsidiary, Aurigene Oncology, has shown positive results in its Phase 1 clinical trial for blood cancer therapy, with 62.5% of patients achieving a complete response. This marks a significant step forward in cancer treatment.

Dr. Reddy's news today

Aurigene Oncology Limited, a subsidiary of Dr. Reddy’s Laboratories, has reported positive results from its first clinical trial of Ribrecabtagene autoleucel (DRL-1801), a new CAR-T cell therapy for multiple myeloma, a type of blood cancer. This breakthrough in cancer treatment marks a significant milestone as it is the first trial of its kind in India to test CAR-T therapy for this condition.

DR. REDDY S LABORATORIES

Trade

6598-66.85 (-1.00 %)

Updated - 10 October 2024
6698.00day high
DAY HIGH
6590.00day low
DAY LOW
9046
VOLUME (BSE)

Clinical trial success

The Phase 1 clinical trial, named the SWASTH study, involved eight patients who had previously undergone multiple treatments for multiple myeloma, with an average of 5.5 prior treatments, including transplants. The trial yielded remarkable results, with all eight patients showing a clinical response to the therapy. Notably, 62.5% of these patients achieved a complete response, demonstrating the potential effectiveness of this new treatment.

Moreover, the therapy exhibited a strong safety profile. None of the patients experienced serious side effects, such as Cytokine Release Syndrome (CRS) or neurotoxicity, which are common concerns in CAR-T cell therapies. These results provide a solid foundation for further research and development.

Moving forward to Phase 2

Following the promising results of the Phase 1 trial, the Drugs Controller General of India (DCGI) has approved the initiation of Phase 2 of the trial, which will involve a larger cohort of patients. This advancement is expected to further evaluate the effectiveness and safety of Ribrecabtagene autoleucel in treating relapsed refractory multiple myeloma patients.

The trial results were recently presented at the 21st annual meeting of the International Myeloma Society in Rio De Janeiro, Brazil, showcasing India’s growing contributions to global cancer research.

With these positive trial outcomes, Aurigene Oncology’s efforts mark a significant advancement in blood cancer treatment. The success of the trial is likely to bolster investor confidence, potentially benefiting Dr. Reddy share price as the company continues its efforts in developing innovative cancer therapies.

Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.

This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

For All Disclaimers Click Here: https://bit.ly/3Tcsfuc

Share this article: 

Read More Blogs

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

8 Lacs + Users

icon-with-text

4.8+ App Rating

icon-with-text

4 Languages

icon-with-text

₹5000+ Cr MTF Book

icon-with-text